The HIV-1 pandemic: does the selective sweep in chimpanzees mirror humankind’s future? by Natasja G de Groot & Ronald E Bontrop
de Groot and Bontrop Retrovirology 2013, 10:53
http://www.retrovirology.com/content/10/1/53REVIEW Open AccessThe HIV-1 pandemic: does the selective sweep in
chimpanzees mirror humankind’s future?
Natasja G de Groot1* and Ronald E Bontrop1,2Abstract
An HIV-1 infection progresses in most human individuals sooner or later into AIDS, a devastating disease that kills
more than a million people worldwide on an annual basis. Nonetheless, certain HIV-1-infected persons appear to
act as long-term non-progressors, and elite control is associated with the presence of particular MHC class I
allotypes such as HLA-B*27 or -B*57. The HIV-1 pandemic in humans arose from the cross-species transmission of
SIVcpz originating from chimpanzees. Chimpanzees, however, appear to be relatively resistant to developing AIDS
after HIV-1/SIVcpz infection. Mounting evidence illustrates that, in the distant past, chimpanzees experienced a
selective sweep resulting in a severe reduction of their MHC class I repertoire. This was most likely caused by an
HIV-1/SIV-like retrovirus, suggesting that chimpanzees may have experienced long-lasting host-virus relationships
with SIV-like viruses. Hence, if natural selection is allowed to follow its course, prospects for the human population
may look grim, thus underscoring the desperate need for an effective vaccine.
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AIDS: facts and figures
Acquired immunodeficiency syndrome (AIDS) is caused
by the human immunodeficiency virus type 1 (HIV-1) and
poses a major threat to human health. At present, over
thirty million individuals are infected worldwide, and
more than twenty five million people have died from AIDS
since the beginning of the pandemic (UNAIDS 2011).
Based on genetic characteristics, the virus strains can be
clustered into different groups designated M, N, O and P.
HIV-1 group M is responsible for the vast majority of in-
fections recorded in human individuals globally [1,2].
Thanks to the currently available anti-retroviral (AR)
drugs, the number of people dying yearly from AIDS
reached a plateau around 2004, and the number has even
begun to decline (UNAIDS 2011). However, it is import-
ant to mention that highly active anti-retroviral therapy
(HAART) does not eradicate HIV-1 [3], and several stud-
ies have demonstrated that discontinuation of HAART
may result in a rapid viral rebound [4-7]. Moreover, AR
therapy carries with it high costs, resulting in only a* Correspondence: groot@bprc.nl
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distribution, and reproduction in any mediumlimited number of HIV-1-infected individuals having ac-
cess to it. Especially in developing countries, where most
of the infected individuals live, AIDS is still a prominent
health problem. Another worry is that sooner or later the
virus may develop resistance to these drugs [8], and the
spread of drug-resistant HIV-1 strains would be devastat-
ing. Therefore, a series of low-cost drugs and, more opti-
mistically, an efficacious vaccine able to protect against
infection are urgently needed.HIV-1 in a nutshell: its genome and infection routes
The genome of HIV-1 is relatively small, approximately 10
kilobases, and encodes a limited number of gene products
(Figure 1). This retrovirus belongs to the group of lentivi-
ruses. Like most retroviruses, the HIV-1 genome contains
the three functional proteins Gag, Pol, and Env, which are
essential for the construction of the virus particle [9]. In
addition, lentiviral genomes encode a number of regulatory
(Tat and Rev) and accessory genes (Vif, Vpr, Vpu, and
Nef). The Tat and Rev proteins are essential for replication
of the virus. The accessory proteins are attached to viral
messenger RNA, but they are not required for replication
of the virus in vitro. However, in vivo these proteins are ne-
cessary for the replication and virulence of the virus [10].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Schematic representation of the HIV-1 genome and its gene products. The arrow indicates the transcription initiation site.
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have hampered the development of broadly efficacious
and efficient anti-retroviral drugs and vaccines. On the
one hand, the virus can cause a persistent infection and
hide in an inactive form in cellular reservoirs. On the
other hand, it can replicate quickly, and − depending on
the copy number present in one individual −may pro-
duce 109 to 1010 particles per day [11,12]. Moreover, the
genome of HIV-1 encodes an error-prone reverse tran-
scriptase characterized by a high mutation rate (approxi-
mately 3 × 10-5 per nucleotide/replication cycle) [13].
This, in combination with a relatively small genome size
and the high viral production rate within a given individ-
ual, may ultimately result in the establishment of a virus
swarm. There is also the risk of emergence of new re-
combinant strains as multiple HIV-1 viruses, which are
prone to exchange genetic material, infect a single cell.
Hence, a high mutation rate in concert with recombin-
ation provides the biological ability for HIV-1 to escape
the immune recognition/control of its host.
HIV-1 enters the human body via mucosal sites, blood-
blood contact, or breast milk [14]. After entry, the virus ei-
ther directly infects CD4+ T cells, is recruited by dendritic
cells (DC), or is taken up by macrophages. The latter two
cell types act as a kind of Trojan horses, and transport
HIV-1 through different layers of epithelial cells to the
lymphoid tissues, where they can transfer the virus to
CD4+ T cells [15,16]. DCs can either internalize HIV-1 into
endosomes, and the cell-surface molecule that is used by
the virus for entry into the cell is the C-type lectin receptor
DC-SIGN [17], or they can recruit HIV-1 virions to their
endosomal compartment, where the virions accumulate at
regions that come into contact with neighboring T cells
(referred to as the infectious synapse) [18]. Macrophages
may phagocytize HIV-1, and can either function as a reser-
voir for long-term persistence of the virus or can be re-
sponsible for the transport and dissemination of the virus.
The “primary” non-syncytium-inducing (NSI) HIV-1
viruses mainly infect CD4+ memory T cells that express
CC-chemokine receptor-5 (CCR5). Later in the course of
the infection, the NSI strains can switch to a syncytium-
inducing (SI) phenotype, which can infect T cells by using
the C-X-C-chemokine receptor-4 (CXCR4) as co-receptor.
This switch is associated with a loss of sensitivity to
chemokines (like RANTES, and MIP-1α and β), a rapid de-
crease in CD4+ T cells, and progression towards AIDS [19].
Moreover, an infection of memory CD4+ T cells that revert
back to a resting state ensues as well, resulting in adormant stage of the virus that is undetectable by the host’s
immune system [20]. In essence, HIV-1 infection and its
subsequent manipulations take place at the heart of the
immune system.
Zoonotic infections: what may happen if we open
Pandora’s box
More than 40 African non-human primate species are
infected naturally with various simian immunodeficiency
virus (SIV) strains, but progression towards AIDS is rarely
observed [21,22]. From among these natural primate
hosts, the SIV infection has been most thoroughly studied
in three species, sooty mangabeys, African green monkeys,
and mandrills, and has led to the insight that non-
pathogenicity need not be linked to effective immune con-
trol. Apparently, many of the species have co-evolved with
SIV infections, and have found ways to manage/control it.
These non-human primates, however, are potential reser-
voirs for viruses that could be spread among related spe-
cies. One example of such a zoonotic transmission is
provided by sooty mangabeys (Cercocebus atys). This spe-
cies, infected naturally with a SIV strain (SIVsm), is consid-
ered to represent the origin of the HIV-2 infection in
humans, causing an AIDS-like disease [23]. The infection
in humans is mostly confined to the West African terri-
tory, and indeed overlaps with the natural habitat of sooty
mangabeys.
Chimpanzees (Pan troglodytes), humankind’s closest liv-
ing relative, can also be infected with SIV [24]. Based on
the geographic distribution as well as on morphological
and genetic data, chimpanzees have been divided into four
different subspecies/populations sharing a common ances-
tor approximately 1.5 million years ago [25-27], and inci-
dences of natural SIVcpz infection have been recorded in
contemporary animals from at least two of the four sub-
species (Figure 2). These SIVcpz-strains appear to have a
mosaic genome, consisting of gene segments from differ-
ent types of SIV strains obtained from distinct Old World
monkey species [28]. This suggests that chimpanzees have
acquired their types of SIV infections by predation on Old
World monkeys sharing the same habitat. In turn, the dif-
ferent HIV-1 groups M, N, O and P, have arisen from at
least four separate introductions of SIV into the human
population. The initiator of the human pandemic (HIV-1
group M) is the SIVcpz strain derived from chimpanzees of
the Central-African subspecies (Pan troglodytes troglo-
dytes) [29] (Figure 2), and the HIV-1 group N also arose























Figure 2 Map of the African continent, highlighting habitats of the four different chimpanzee subspecies. Populations that show evidence
of contemporary natural infections with SIVcpz strains are Pan troglodytes troglodytes (light orange) and P.t. schweinfurthii (dark orange). Superimposed is
a diagram illustrating the cross-species transmission events that led to the emergence of HIV-1 group M, the initiator of the human pandemic [28]. The
lower panel in the figure illustrates the speciation events in the homo-pan lineage. The arrow indicates the putative time span of the MHC repertoire
reduction in the pan lineage.
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[30,31], in which there is an indication that P.t.t. animals
are the source of SIVgor [32].
Chimpanzees and AIDS
Apart from humans, chimpanzees are one of the non-
human primate species that is susceptible to infection
with HIV-1. Recently, it has been shown that pig-tailed ma-
caques can also be infected through a modified HIV-1 strain
that only differs in the vif gene [33,34]. In the past, a sub-
stantial number of West-African chimpanzees (P.t.verus)
were experimentally infected with different HIV-1 strains,
but most of these animals seem to be relatively resistant
to developing AIDS [35,36]. These experiments were
conducted before it was known that HIV-1 was derived
from a zoonotic transmission of a virus that has its roots in
a chimpanzee reservoir. In the late 1980s and early 1990s,
the first chimpanzees to be infected naturally with an HIV-1
-related lentivirus were discovered [37-39]. Additional nat-
ural SIVcpz infections in captive and wild-living chimpanzees
were described later [40,41]. Some of these chimpanzees
were kept under close surveillance for long periods, but
signs of an AIDS-like disease were not seen. Moreover,
transmission of one of the viruses to West-African chimpan-
zees (animals in which natural infection with SIVcpz is not
observed) also did not result in the progression to AIDS
[42]. Recently, population analyses have shown that
wild-ranging East-African chimpanzees (P.t. schweinfurthii)
experience natural infections with SIVcpz. For one of the po-
pulations, evidence of AIDS-like symptoms has been docu-
mented [43], and AIDS-related symptoms have also been
described for a naturally infected Central-African chimpan-
zee [44]. In addition to these observations of AIDS in
SIVcpz-related infections, there is one case documenting that
chimpanzees can develop AIDS after experimental infection
with HIV-1 [45]. This chimpanzee of West-African origin
was infected with three different HIV-1 isolates. The animal
eventually developed AIDS, and subsequent analysis showed
that a recombinant HIV-1 strain had emerged. Three other
chimpanzees that were afterwards infected with this recom-
binant strain all developed signs of AIDS-like disease [46].
This set of experiments shows that viruses that have been
edited in the human population, and that are re-introduced
into their original host species, can cause AIDS. Thus, es-
cape from immune control in chimpanzees is possible in ex-
ceptional cases, even within a species considered to be
relatively resistant.
Control of AIDS development in humans: an introduction
to the MHC
In HIV-1-infected human cohorts, certain individuals do
not progress towards AIDS. Some of these long-term non-
progressors (LTNP)/elite controllers (ECs) have been
infected for more than two decades [47], and theirsituation appears to resemble that of HIV-1-infected
chimpanzees in terms of their relative resistance to devel-
oping AIDS. The LTNP/EC status in humans is strongly
associated with the presence of particular major histocom-
patibility complex (MHC) class I molecules, such as HLA-
B*27:05 and -B*57:01 [48-54].
The MHC plays a central role in the induction of adap-
tive immune responses, and encodes two clusters of
cell-surface proteins. In humans, these molecules are desig-
nated HLA-A, -B, and -C (class I cluster), and -DP, -DQ,
and -DR (class II cluster), and almost all these genes dis-
play abundant levels of polymorphism [55]. MHC class I
antigens are expressed on virtually all nucleated cells, and
generally present peptides of 8-10 amino acids in length.
One of the biological functions of MHC class I molecules
is to sample degraded peptide fragments from pathogens
that are able to establish intracellular infections. In most
cases, such peptides are derived from viruses trying to ma-
nipulate the intracellular machinery of the host cell in favor
of their own replication purposes. MHC class II molecules,
on the other hand, display differential tissue distribution
and usually bind substantially longer peptides. They sample
degraded peptide fragments from pathogens that are
establishing extra-cellular infections, or that have life stages
that are taking place outside of the host cell. In the case of
an intracellular infection, the immune system will try to kill
the target cell by inducing apoptosis-mediated lysis by
CD8+ cytotoxic T cells (CTL). Extra-cellular infections are
usually eliminated by antibodies that are generated by B
cells under the control of CD4+ T helper cells.
In order to initiate an immune response, each individual
will present a range of antigenic peptides as dictated by
their unique HLA repertoire. Thus, MHC polymorphism
warrants that many individuals within a given population
have the capacity to generate unique adaptive immune re-
sponses to eliminate infections. In other words, MHC poly-
morphism minimizes the chance that a given pathogen will
eliminate an entire population. Several pathogens have
evolved different ways to interfere with the MHC class
I and II antigen presentation pathways in order to avoid im-
mune recognition [56-59]. Indeed, it has been suggested
that in human populations exposed to HIV-1 there is
enrichment for particular HLA specificities [60,61].
The MHC and resistance to the development of AIDS in
chimpanzees
Grosso modo, humans and chimpanzees share the same
MHC class I and II loci. However, chimpanzees possess
an additional oligomorphic locus designated Patr-AL (A-
like), which is characterized by a differential haplotype
distribution and low expression levels [62,63]. An over-
view of the reported number of alleles for each locus is pro-
vided (Table 1). With regard to lineages, in comparison to
humans, chimpanzees have a reduced MHC class I
Table 1 Number of alleles detected for Mhc class I and II
loci in humans (HLA) and chimpanzees (Patr)
Locus HLA Patr
A 2188 33












#Individuals analyzed >> ≈100
Data were retrieved from the databases www.ebi.ac.uk/imgt/hla [70] and
www.ebi.ac.uk/ipd/mhc/nhp [71].
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lack the evolutionary equivalents of particular HLA lineages
became evident in serological studies [64]. In humans, the
HLA-A locus alleles are divided into two lineages compris-
ing six families (Table 2) [65,66], and the experiments of
van Rood et al. [64] showed that chimpanzees lack the
HLA-A2 related serotypes. Subsequent molecular studies
suggested that chimpanzees might only possess the equiva-
lents of the HLA-A1/A3/A11/A30 family [67]. Although
the number of animals tested in this initial study was rela-
tively small, the outcome was unexpected. Humans and
chimpanzees are each other’s closest living relatives, and
they shared a common ancestor about 5 million years ago
[68]. Thus, the most logical explanation would be that
humans and chimpanzees share for the A and B loci the
same lineages, since they were inherited in a trans-species
mode of evolution [69].
As a follow-up to McAdam’s study [67], the MHC class
I repertoire of a pedigreed West-African chimpanzee col-
ony comprising more than 30 wild-caught founder ani-
mals was analyzed. Again, only orthologs of the HLA-A1/
A3/A11/A30 family were encountered [72]. Moreover,








HLA-A80research teams, and of small numbers of Central- and
East-African chimpanzees, also provided data indicating
only the presence of HLA-A1/A3/A11/A30 family
orthologs [72-76]. Although the results suggest that there
was a repertoire reduction at the MHC class I region in
chimpanzees, conclusions in this direction should be ar-
rived at cautiously. The presence of one particular omni-
present HLA-A-like family in chimpanzees can, in theory,
also be explained by convergent evolution. Additionally,
the imbalance in sample size between the number of
chimpanzees and humans analyzed for their MHC reper-
toire can hamper an accurate interpretation of the data.
For instance, one can argue that particular alleles and/or
lineages were missed in chimpanzees due to a limited
sample size. In addition, the MHC class I and II gene
products of different species/populations may experience
different sorts of natural selection, depending on their
habitat and on the pathogens that are present. Another vi-
able explanation could be that there was an expansion of
the HLA class I lineages. To answer such questions, we
designed a study that investigated the influence of selec-
tion operating on the classical MHC class I loci. This in-
volved the comparison of intron variation of chimpanzee
and human MHC class I alleles. The different intron 2 var-
iations observed in both species are clustering into various
lineages, of which some are shared (Figures 3 and 4). On
the basis of two well-defined populations, the MHC class I
intron 2 data regarding twenty-five randomly chosen hu-
man Caucasian individuals [77] were compared with the
data regarding our twenty-five P.t.v. chimpanzees. The χ2
statistics showed that the intron 2 variation found in
humans is 2.56 times higher (confidence interval (CI) 95%
is 0.87-7.55, P = 0.07) for the MHC-A locus, and 2.64
times higher (CI 95% is 1.20-5.82, P = 0.01) for the B locus
[78]. The human cohort used, however, was not typed for
the HLA-C locus, and therefore we have reanalyzed the
data using a different human cohort that is typed at high-
resolution level for HLA-A, -B, and -C (random panel
IHB). To determine for all three loci whether the number
of intron 2 alleles detected in humans is significantly
higher as compared to that in chimpanzees, the difference
in unique number of alleles (Δne) was calculated by using
bootstrap analyses. Additionally, for each locus, the ratio
of the number of unique alleles in humans divided by the
number of unique alleles in chimpanzees was calculated.
The Δne and the ratios of unique alleles were considered
statistically significant if their confidence interval did not
enclose 0 or 1, respectively. The analyses revealed that all
three loci show a statistical significant difference for the
Δne and ratio in humans versus chimpanzees (Table 3).
Thus, the approach confirms that chimpanzees indeed ex-
perienced a selective sweep targeting the MHC class I rep-
ertoire. The repertoire condensation was claimed to
predate the (sub)speciation of chimpanzees, as the same
Figure 3 Pie charts showing the presence/absence of MHC
class I intron 2 lineages in humans and chimpanzees. A colored
section in a pie indicates the presence of a particular intron 2 lineage
in that species; red for MHC-A, blue for MHC-B, and orange for MHC-C.
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tions of chimpanzees, and was calibrated to have happened
approximately 2-3 million years ago [78] (Figure 2). This
suggests that in the distant past, ancestors of the contem-
porary chimpanzee populations must have been in close
contact with each other, and that a plague may have af-
fected the entire species. The fact that chimpanzees experi-
enced a repertoire reduction in the MHC class I region,
and the knowledge that most chimpanzees infected experi-
mentally with HIV-1 are relatively resistant to developing
AIDS, resulted in the hypothesis that the ancient repertoire
reduction may have been caused by an HIV-1/SIVcpz-like
or a closely related retrovirus [78].
A successive comparative genomic approach, using micro-
satellite markers located in the MHC region and markers
mapping at a variety of other chromosomes, revealed that
both chimpanzees and humans show similar amounts of
variation for most of the non-MHC markers. Nonetheless, a
significant lower allelic variation for the majority of the
markers mapping in the chimpanzee MHC region was docu-
mented [79]. These data support the claim that chimpanzees
possess a reduced MHC repertoire. Subsequent multi-locus
demographic analyses highlighted the fact that chimpanzees
experienced a selective sweep that mainly targeted the
chromosomal segment carrying the MHC class I region [79].The evolution of chimpanzee MIC genes: further
substantiation of selection
Activated CD4+ memory T cells are selectively and rap-
idly depleted after an HIV-1/SIV infection [80,81]. This
cell type is present in abundance in the intestine, but
other mucosal surfaces (lung, vagina) that are frequently
exposed to environmental pathogens also contain a high
percentage of activated lymphocytes [82]. In humans
and macaques in particular, the intestine is the promin-
ent site of CD4+ T-cell depletion during the first few
weeks after exposure to HIV-1/SIV [81,83]. The major
histocompatibility complex class I chain-related gene
(MIC) molecules are highly expressed on the gastro-
intestinal epithelium [84], and the genes encoding these
molecules map to chromosome 6 within the MHC re-
gion. In humans, seven genes (MICA to MICG) have
been distinguished, though only the MICA and -B genes
produce functional transcripts and display high levels of
polymorphism [70]. The molecules are thought to be in-
volved in signaling stress to the immune system.
Chimpanzees appear to have only one functional MIC
gene (localized near the Patr-B locus), which has an
intermediate character resembling in part the human
MICA and -B genes. A large ancestral deletion of 95 kb
resulted in the birth of a hybrid Patr-MICA/B gene [85].
We have investigated MIC gene polymorphism in chim-
panzees, and found that the Patr-MICA/B fusion gene
controls only one lineage showing moderate allelic vari-
ation [86]. Thus, as compared to humans, chimpanzees
have a reduced MIC gene repertoire, which is consistent
with the selective sweep observed for the Patr-B locus.
Moreover, the hybrid MICA/B gene appears to represent
a fixed entity in all chimpanzee (sub)species. This is pe-
culiar, as most other primate species possess haplotypes
that carry both MICA and -B genes. Hence, somewhere
during chimpanzee evolution a haplotype with a hybrid
MICA/B gene was generated, and all other haplotypes
carrying MICA and -B genes have gone missing. As the
MICA/B gene maps next to the Patr-B gene, it is pos-
sible that selection on particular B alleles favored the
preferential selection of this hybrid MIC gene by way of
a piggyback effect. However, it cannot be excluded that
the hybrid MICA/B gene itself, or the combination of
this gene with particular Patr-B alleles, provided a se-
lective advantage.
In humans, MIC is the ligand for the NKG2D receptor,
which is expressed on natural killer (NK) cells, γδ T cells,
and particular CD8+ αβ T cells [87]. A cellular “stress” sig-
nal, triggered for instance by a viral infection or malignant
transformation, may upregulate the expression of MIC,
which can ultimately lead to an immune response. The
Patr-MICA/B fusion molecule is recognized by human
Vδ1 γδ T cells specific for MICA and B, suggesting a con-
served recognition site [88]. In addition, the NKG2D
Figure 4 MHC class I intron 2 sequences in humans (HLA) and chimpanzees (Patr). Only the polymorphic nucleotide positions are
indicated. Identity to the consensus sequence (depicted at the top) is indicated by dashes. Substitutions and inserts are depicted by the
conventional one-letter code; deletions are marked “x”. For instance, “-/A” indicates that differences in a particular sequence have been reported
in the literature. The brackets indicate the division of the intron 2 alleles into lineages, and this is based on phylogenetic analysis. (The figure is
adapted from De Groot N.G. et al., PNAS 99, 11748-11753, 2002).
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[89]. Whether MIC plays a role in NK effector responses
against HIV-1/SIVcpz has yet to be proven, as does the func-
tional role of the Patr-MICA/B gene in viral infections [86].
Signs of selection beyond the MHC in chimpanzees
HIV-1 targets CD4+ T cells by the use of the CD4 recep-
tor and different co-receptors. Orthologs of the humanCD4 receptor, and of the CCR5 and CXCR4 co-receptors,
are present in chimpanzees. In humans, several genetic
CCR5 modifications are associated with resistance/suscep-
tibility to HIV-1 infection [90]. The CCR5 variant that
possesses a 32-base pair deletion (CCR5-Δ32) conferring
nearly complete resistance to HIV-1 infection in homozy-
gous individuals is present in approximately 1% of the
Caucasian population [91]. In chimpanzees, no 32-base
Table 3 Difference in the number of unique alleles
(Δne (95% CI)) and the ratio of unique alleles (95% CI) in
humans as compared to chimpanzees for the different
MHC class I loci
Locus Δne (95% CI) Ratio (95% CI)
Mhc-A 4.00 (2.00 - 7.00) 1.80 (1.33 - 2.40)
Mhc-B 5.00 (2.00 - 8.00) 1.63 (1.22 - 2.17)
Mhc-C 6.00 (3.00 - 8.00) 2.25 (1.60 - 3.67)
For the statistical analysis, 50 haplotypes were re-sampled 100,000 times and
with replacement, separately for both species. The Δne was calculated by
subtracting the ne of the chimpanzee from the ne of the human, and the ratio
of unique alleles in the two species was calculated by dividing the ne of the
human by the ne of the chimpanzee. The median was defined as the 50,000
th
value and the lower and upper confidence limits were defined as the 250th
and 99,750th values emanating from the bootstrapping. Calculations were
performed using the R statistical package (version 2.15.3).
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the relative resistance of chimpanzees to developing AIDS
after an HIV-1 infection cannot be attributed to this gen-
etic modification [92-94]. Variations in the human 5′ cis-
regulatory region of CCR5 (5′CCR5) were found to be as-
sociated with different transcription levels that influence
HIV-1 entry and may affect disease progression [95].
Hence, the human 5′CCR5 haplotype that shows the low-
est promoter activity resulting in control of AIDS develop-
ment is the most common haplotype in chimpanzees [96].
By assuming a wide range of demographic histories,
Wooding et al. [96] demonstrated that the human 5′CCR5
promotor region experienced balancing selection, and that,
in contrast, the chimpanzee equivalent was affected by a
selective sweep. This suggests that if the chimpanzee 5′
CCR5 promotor region is linked to functional variants that
influence progression to AIDS, it may contribute to the
relative resistance of chimpanzees to developing AIDS after
an HIV-1/SIVcpz infection. Corresponding to this finding,
MacFie et al. [97] demonstrated differential patterns of
diversity for the HIV-related loci CCR5, CXCR4, and
CX3CR1 in three chimpanzee subspecies (West- and
Central-African, and Nigeria-Cameroon) [97]. For the
CCR5 locus, they showed that it has low levels of diversity
for all three subspecies, and this appeared to be tightly cen-
tered, as flanking loci displayed normal variation in all
subspecies. The results suggest that the CCR5 locus experi-
enced a selective sweep and that this may have predated
subspeciation. For the Central-African chimpanzees, nat-
ural infections with SIVcpz are documented [39], and a se-
lective sweep at the CCR5 locus may be related to recent
co-evolution with SIVcpz. For the other two subspecies, nat-
ural infections with SIVcpz are not documented in the con-
temporary living animals [44,98]. The fact that these
subspecies do show evidence for selection at CCR5 could
indicate that they were infected with SIVcpz-like virus
strains in the past, and that infections are rare or absent at
present. Alternatively, the entire ancestral chimpanzee
population may have been infected with an SIVcpz-likevirus, resulting in a selection event at that stage for which
the signature still can be measured. Depending on novel in-
fections with SIVcpz strains, particular selection forces are
still operative.
Different cellular restriction factors, such as tripartite
motif protein 5 alpha (TRIM5α) and apolipoprotein B
mRNA-editing enzyme 3G (APOBEC3G), can target the
intracellular replication of HIV-1 [99]. The APOBEC3G
gene underwent strong positive selection, and during
primate evolution this gene experienced several episodes
of adaptations [100]. Polymorphisms in the human
APOBEC3G gene have been documented, but its relation-
ship with control of viral replication needs further investi-
gation [101]. The chimpanzee APOBEC3DE, one of the
other seven members of the APOBEC family, has potent
antiretroviral activity against HIV-1. This is thought to be
driven by an ancient lentiviral selective pressure dating
back approximately 2 to 6 million years [102], which is
consistent with our hypothesis that chimpanzees experi-
enced a selective sweep caused by HIV-1/SIVcpz-like or a
closely related retrovirus prior to chimpanzee (sub)speci-
ation [78].
In addition, chimpanzees experienced selection on the
fourth component (C4) gene of the complement system
that maps in the MHC class III region [103]. Most
humans possess two copies of the gene, designated C4A
and C4B, and both genes are known to display size poly-
morphism due to the insertion of a complete endogenous
retrovirus of 6.3 kb [104]. The long version of the C4A
gene is found in humans, orangutans, and a variety of Old
World monkeys [103,105]. However, chimpanzees only
possess the equivalents of the short versions of the C4A
and C4B genes. Since the presence of the long C4A gene
predates human and Old World monkey speciation, the
equivalent of this gene has most likely been lost during
chimpanzee evolution.
Therefore, different research angles provide evidence
that chimpanzees, as compared to humans, have experi-
enced selection operating on the MHC and other genomic
regions during their evolution. Chimpanzees shared a
common ancestor with the bonobo (Pan paniscus) ap-
proximately 2 million years ago. A recent comparison of
the bonobo and chimpanzee genome revealed that in
chimpanzees, the MHC region in particular has experi-
enced positive selection [106].
Ancient selective sweep in chimpanzees most likely
caused by an SIV-like retrovirus: supporting data from
functional studies
Control of AIDS development in HIV-1-infected human
cohorts is strongly associated with the presence of HLA-B
*27:05 and -B*57:01 [48,52-54,60], and adaptive immune
responses to the HIV-1 Gag protein are thought to play an
important role in the control of viral replication [107,108].
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measure immune responses to this protein in chimpan-
zees. More specifically, we investigated whether the select-
ive sweep had resulted in the preferential selection of Patr
class I allotypes, and, if so, whether these allotypes could
target similar HIV-1/SIV Gag regions as do HLA mole-
cules associated with control of AIDS development. There-
fore, the peptide-binding motifs of four Patr class I
molecules, occurring at high frequency in a thoroughly
characterized West-African chimpanzee population, were
determined [109]. The obtained motifs were used to scan
the HIV-1/SIVcpz Gag proteins for potential CTL epitopes,
and the relevant peptides were subsequently tested in bind-
ing studies. Two of the studied Patr molecules have
peptide-binding motifs that resemble those of HLA-B*27
or -B*57, and can target similar areas of the HIV-1/SIVcpzFigure 5 Human (HLA) and chimpanzee (Patr) peptide-binding motifs
that are potentially targeted. P2 and PΩ (carboxyl-terminus) represent th
that are preferred on these positions are indicated by the conventional on
brackets. Patr-B*01:01 has a peptide-binding motif that resembles that of H
resembles that of HLA-B*27:05. Parts of the Gag consensus sequences of H
in the SIVcpz consensus indicates a variable position. The HLA-B*27 and -B*
class I molecules, blue arrows indicate the potential Gag epitopes that are
determined in peptide-binding competition assays, high (1) or intermediat
molecule are indicated [109].Gag protein (Figure 5). In addition, the two other studied
allotypes, although divergent in their peptide-binding
anchors, also appear to target the conserved areas of
the HIV/SIVcpz proteome similar to the AIDS-controlling
HLA-B*27 and -B*57 molecules. Thus, particular human
and chimpanzee allotypes share similar qualitative func-
tional characteristics.
Recently, an in silico approach comparing human and
chimpanzee MHC class I alleles illustrated that, with re-
gard to the peptide-binding repertoire, the Patr-A mole-
cules show signs of a selective sweep [110]. The Patr-A
allotypes, in general, appear to have promiscuous binding
profiles, and as a consequence they can target conserved
areas of the Gag protein. The chimpanzee-specific Patr-
AL molecule has a peptide-binding motif similar to HLA-
A*02 [111]. However, as compared to the classical MHCof relevant MHC class I molecules, and the Gag protein regions
e anchor-binding positions of the MHC class I molecules; amino acids
e-letter code, whereas tolerated amino acids are indicated between
LA-B*57:01, and Patr-B*03:01 has a peptide-binding motif that
IV-1 (HBX2) and SIVcpz are given (www.hiv.lanl.gov). A lower-case letter
57 CTL epitopes are indicated by red arrows. For the respective Patr
tested in peptide-binding studies. Based on IC50 (μM) values
e (2) binding affinities of the peptides to their respective MHC class I
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pression level and present only on approximately 50% of
the chimpanzee MHC haplotypes), and further investiga-
tion is needed as to whether this molecule contributes sig-
nificantly to adaptive immune responses.
In the founder population that we analyzed thoroughly,
94% of the chimpanzees possess at least one of the four
Patr class I allotypes studied (Figure 5). Moreover, many
chimpanzees were observed to express multiple allotypes,
which are able to bind peptides derived from various con-
served Gag regions. This has led us to suggest that chim-
panzees may have developed a “double-lock” strategy to
respond to an HIV-1/SIVcpz infection, meaning that the
chance of the virus escaping by mutations has been se-
verely diminished. As only four Patr allotypes have been
studied at this point, this quantitative aspect of the im-
mune response might become more prominent if more
peptide-binding motifs become available. Evaluation of the
immune response data of three different HIV-1-infected
chimpanzees revealed that the animals displayed broadly
reactive CTL responses to conserved epitopes of the Gag
protein [109,112,113]. Thus, the functional characteristics
of the chimpanzee MHC class I repertoire suggest that the
ancient selective sweep was caused by a lentiviral pan-
demic. The effect of this sweep can still be measured, as
most extant chimpanzee populations appear to have a re-
duced MHC class I repertoire. However, most animals do
possess (multiple) allotypes with functional characteristics
similar to the AIDS-controlling HLA-B*27/B*57 mole-
cules in humans.
There is evidence that the selective sweep or subsequent
selection processes must have been more prominent in
West-African chimpanzees than in other chimpanzee pop-
ulations [96,97,114]. Population separation may have
influenced this. Moreover, chimpanzees and their ances-
tors were most likely infected through predating on differ-
ent monkey species that are infected with disparate types
of SIV strains. Thus, depending on the monkey species
predated upon, and their respective SIV infection, reper-
toires could have been edited in slightly different manners
[109]. Predation may result in ongoing new infections. As
a consequence, new recombinant SIVcpz strains may be
generated occasionally [115], and some of these strains
may develop pathogenic characteristics. Thus, non-human
primates are challenged by SIV infections for long periods
of time, and must have developed ways to control the de-
velopment of AIDS [22].
In rhesus macaque SIV models, currently used widely to
study immunopathogenesis as well as to modulate the im-
munological responses induced by HIV-1 vaccine and vac-
cine components, EC is correlated with immune responses
primarily directed towards the proteins Vif and Nef
[116,117]. The macaque class I allotype Mamu-B*008,
which is involved in EC, has a peptide-binding motif thatresembles HLA-B*27, and only three CD8+ T-cell epitopes
were shown to be responsible for the T-cell responses con-
trolling replication of the pathogenic SIVmac239 in these
ECs [118]. Two of the epitopes, Vif RL9 and Nef RL10, are
conserved, and similar motifs are present in SIVcpz and
HIV-1 (Figure 6). Modeling the peptide binding of the pro-
teins Vif and Nef to HLA-B*27:05 and the four studied Patr
class I allotypes showed that they can target these con-
served regions of Vif RL9 and Nef RL10 as well (Figure 6).
This may suggest that, in different species, evolutionarily
unrelated MHC class I molecules possessing similar pep-
tide binding motifs are important for control of the
lentiviral infection.Conclusions
The selective sweep in chimpanzees: a mirror of
humankind’s future?
A remaining question concerns how many chimpanzees
died during the pandemic that may have been caused by
an HIV-1/SIVcpz-like retrovirus. This is a difficult ques-
tion to answer, but it is likely that the number must have
been huge. Natural history has provided a few examples
in which the introduction of a “novel” virus into a naïve
population resulted in mass mortality. For instance, con-
tact between European individuals and the native popu-
lation of America led to the death of millions of
Amerindians as a result of infection with measles, small
pox, and other viruses [120]. The deliberate infection
of rabbits with the myxoma virus exterminated ap-
proximately 99% of the rabbit population in Australia
[121]. Natural infections in animals can also have
strong effects on population size, as is illustrated by the
rinderpest epidemic in African buffalo [122], and by the
decimation of seals by morbilli and influenza viruses
[123,124].
Modern humans, who have their cradle in Africa, have
existed for about 150,000-200,000 years [125], and dis-
play an impressive amount of MHC class I polymorph-
ism [126]. Recent cohort studies have demonstrated that
particularly those individuals equipped with HLA-B*27
and/or -B*57 are able to control an HIV-1 infection
[49,50]. Nevertheless, in these individuals one also sees
that an escape by the virus may occur, although mostly
with a cost to viral fitness [127-129]. Furthermore, there
is an additional effect on viral control caused by a
phenomenon such as heterozygous advantage [130,131].
Chimpanzees may reflect the latter stages of selection.
First, the Patr molecules have the ability to respond to
an HIV-1/SIVcpz infection. Second, a quantitative aspect
seem to be operative in chimpanzees, as each individual
may possess several Patr molecules that can respond to
different conserved parts of the HIV-1/SIVcpz proteome,
termed “double lock” strategy.
Figure 6 Conserved regions around the Mamu-B*008 epitopes Vif RL9 and Nef RL10 that can be targeted by HLA and Patr class I
molecules. P2 and PΩ (carboxyl-terminus) represent the anchor-binding positions of the MHC class I molecules; amino acids that are preferred
on these position are indicated by the conventional one-letter code, whereas amino acids indicated between brackets are tolerated. The epitopes
Vif RL9 and Nef RL10 in SIVmac239 are indicated by a red line [118]. For HIV-1 (HBX2) and SIVcpz the consensus sequences surrounding these Vif
and Nef epitopes are given (www.hiv.lanl.gov). A lower-case letter in the SIVcpz consensus indicates a variable position. A red arrow indicates that
the respective MHC class I molecule is predicted to target the SIVmac239 consensus sequence. A grey arrow indicates prediction of the MHC
molecule to target the SIVcpz/HBX2 consensus sequence. SB stands for solid binding (affinity < 100 nM); WB stands for weak binding (affinity
between 100 to 700 nM). Binding affinity of the peptides was predicted using the NetMHCpan algorithm [119], except for Patr-B*03:01 (white
dotted arrows), for which binding was assumed based on agreement in the anchor binding positions.
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preferential selection of Patr class I allotypes that can
target conserved areas of Gag similar to those targeted
by HLA-B*27/B*57. In humans, these allotypes also
seem to predispose for the immune-mediated patholo-
gies ankylosing spondylitis and psoriasis, respectively.
Evidence for the presence of these immune-mediated
pathologies in chimpanzees is very low [132,133]. In
humans, the exact role of HLA-B*27 in ankylosing spon-
dylitis is also not known. Moreover, chimpanzee MHC
class I molecules can target similar conserved motifs
such as HLA-B*27/B*57, but this does not tell us
whether the structure of the chimpanzee MHC class I
molecules are comparable to HLA-B*27/B*57, as these
molecules belong to different ancestral lineages [72,112].
In general, a virus survives best if it is able to replicate
and disseminate itself within a population without killing
all of its hosts. Such a host/virus state of equilibrium is, for
instance, reached in different non-human primate species
that are infected naturally with SIV strains. For HIV-1 and
its human hosts, the battle seems to be in full swing, and
without proper treatment the human population may behit hard by this pandemic. For humans up until now, con-
trol of HIV-1 replication, without treatment, is significantly
associated with the MHC region, in particular with the
MHC class I molecules HLA-B*27:05 and -B*57:01, which
can target conserved regions of the HIV-1 Gag protein.
The observations adduced in this review have important
consequences for vaccine design, as different HLA specific-
ities may target different sections of the HIV-1 proteome.
One major implication is that many human individuals
may not possess HLA class I molecules that have the cap-
acity to bind conserved HIV-1 epitopes that are associated
with control of AIDS development. A truly protective vac-
cine has not yet been reported. Therefore, until that mo-
ment arrives, prevention of the infection itself will be, for
the individual, one of the most important goals as regards
surviving the current HIV-1 pandemic.
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